Why the study?
Does the combination of dihydroergotamine and heparin improve the prevention of deep vein thrombosis compared to low-dose heparin alone?
Does the combination of dihydroergotamine and heparin improve the prevention of deep vein thrombosis compared to low-dose heparin alone?
The combination of dihydroergotamine and heparin appears superior to low-dose heparin alone for preventing deep vein thrombosis by targeting multiple aspects of Virchow's triad.
Answers are grounded in this paper and cite their sources.
May support dihydroergotamine-heparin for DVT prophylaxis in select settings; leaves open confirmation by contemporary randomized trials.
Dihydroergotamine(DHE)-heparin combination offers a unique treatment modality for the prevention of deep vein thrombosis. The combination appears to affect all 3 limbs of Virchow's triad: hypercoagulability, venous stasis, and endothelial damage. In most efficacy studies, data indicated that the combination of DHE 0.5 mg and heparin 5000 IU was superior to low-dose heparin alone. Even when the efficacy of DHE-heparin was the same as that of heparin alone, the use of the combination allowed for a decrease in the heparin dose required.
No takes yet. Share an insight, caveat, or question.
Barone et al. (1986) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: